| Bioactivity | TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain[1]. | ||||||||||||
| Target | nAChR | ||||||||||||
| In Vivo | TQS (1 or 4 mg/kg; i.p.) reduces the expression of LPS-induced IκB mRNA, CD11b mRNA and regulates microglial morphological changes in the hippocampus[1]. Animal Model: | ||||||||||||
| Name | TQS | ||||||||||||
| CAS | 353483-92-8 | ||||||||||||
| Formula | C22H20N2O2S | ||||||||||||
| Molar Mass | 376.47 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Abbas M, et al. The α7 nicotinic acetylcholine receptor positive allosteric modulator attenuates lipopolysaccharide-induced activation of hippocampal IκB and CD11b gene expression in mice. Drug Discov Ther. 2017;11(4):206-211. |